Author

Kanchan Ajbani

Observed names: Ajbani, Kanchan, K Ajbani, K. Ajbani, K. K. Ajbani, Kanchan K Ajbani

Institution: P. D. Hinduja Hospital and Medical Research Centre

Observed institutions: Johns Hopkins University, P. D. Hinduja Hospital and Medical Research Centre

ORCID: 0009-0008-7314-5805

Observed ORCID: 0009-0008-7314-5805

OpenAlex ID: A5110216252

Totally Drug-Resistant Tuberculosis in India

2011 · Z. F. Udwadia, R. A. Amale, et al. · Clinical Infectious Diseases · 542

Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai

2014 · M. Kazi, L. Drego, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 87

Evaluation of the Bactec Mgit 960 Tb System for Recovery and Identification of Mycobacterium Tuberculosis Complex in a High Through Put Tertiary Care Centre

2009 · C Rodrigues, S Shenai, et al. · Indian Journal of Medical Microbiology · 83

PDF

Targeted next generation sequencing directly from sputum for comprehensive genetic information on drug resistant Mycobacterium tuberculosis

2021 · Priti Kambli, Kanchan Ajbani, et al. · Tuberculosis · 58

Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables*

2015 · Priti Kambli, Kanchan Ajbani, et al. · International Journal of Mycobacteriology · 58

Evaluation of Genotype MTBDRsl Assay to Detect Drug Resistance Associated with Fluoroquinolones, Aminoglycosides and Ethambutol on Clinical Sediments

2012 · Kanchan Ajbani, Chaitali Nikam, et al. · PLoS ONE · 51

PDF

Mutation Detection and Accurate Diagnosis of Extensively Drug-Resistant Tuberculosis: Report from a Tertiary Care Center in India

2011 · Kanchan Ajbani, Camilla Rodrigues, et al. · Journal of Clinical Microbiology · 50

Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay

2014 · Priti Kambli, Kanchan Ajbani, et al. · Tuberculosis · 44

Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden Countries

2014 · Kanchan Ajbani, Shou-Yean Grace Lin, et al. · Antimicrobial Agents and Chemotherapy · 42

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

2022 · Antimycobacterial Susceptibility Testing Group, Sophia B. Georghiou, et al. · European Respiratory Journal · 35

PDF

Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations

2015 · P. Kambli, K. Ajbani, et al. · The International Journal of Tuberculosis and Lung Disease · 35

Rapid Diagnosis of Extensively Drug-Resistant Tuberculosis by Use of a Reverse Line Blot Hybridization Assay

2011 · Kanchan Ajbani, Anjali Shetty, et al. · Journal of Clinical Microbiology · 34

Defining multidrug-resistant tuberculosis: correlating GenoType MTBDR plus assay results with minimum inhibitory concentrations

2015 · Priti Kambli, Kanchan Ajbani, et al. · Diagnostic Microbiology and Infectious Disease · 27

Can inhA mutation predict ethionamide resistance? [Short communication]

2012 · V. Vadwai, K. Ajbani, et al. · The International Journal of Tuberculosis and Lung Disease · 23

Clinical outcomes and safety of colistin in treatment of gram negative infections: A prospective observational study

2016 · Kinnari Desai, Mubin Kazi, et al. · The Egyptian Journal of Critical Care Medicine · 18

PDF

Multiplex PCR to detect pAmpC β-lactamases among enterobacteriaceae at a tertiary care laboratory in Mumbai, India

2018 · Mubin Kazi, Kanchan Ajbani, et al. · Microbiology · 16

A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis

2016 · M. Seifert, K. Ajbani, et al. · The International Journal of Tuberculosis and Lung Disease · 16

Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay

2014 · A. P. Trollip, D. Moore, et al. · The International Journal of Tuberculosis and Lung Disease · 16

Treatment of drug-resistant tuberculosis

2011 · Kanchan Ajbani, Rajeev Soman, et al. · The Lancet Infectious Diseases · 15

Redefining MTBDRplus test results: what do indeterminate results actually mean?

2016 · C. Nikam, R. Patel, et al. · The International Journal of Tuberculosis and Lung Disease · 13

Diagnosis and Management of Osteoarticular Tuberculosis: A Drastic Change in Mind Set Needed—It is Not Enough to Simply Diagnose TB

2020 · Vikas M. Agashe, Camilla Rodrigues, et al. · Indian Journal of Orthopaedics · 12

Interpreting very low Mycobacterium tuberculosis detected on Xpert Mycobacterium tuberculosis/rifampicin

2019 · Camilla Rodrigues, Kanchan Ajbani, et al. · Lung India · 12

Evaluation of CSF pyrosequencing to diagnose tuberculous meningitis: A retrospective diagnostic accuracy study

2021 · Kanchan Ajbani, Mubin Kazi, et al. · Tuberculosis · 9

Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens

2018 · Kanchan Ajbani, Mubin Kazi, et al. · Tuberculosis · 9

Pyrosequencing to resolve discrepant Xpert MTB/RIF and Mycobacterial Growth Indicator Tube 960

2018 · Camilla Rodrigues, Kanchan Ajbani, et al. · Lung India · 9

Works count: 44

Citation count: 1,357

H-index: 16

I10-index: 22